- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01732263
Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
22. juni 2021 opdateret af: Shire
A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects
The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
44
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater, 33014
- Clinical Pharmacology of Miami
-
Orlando, Florida, Forenede Stater, 32809
- Orlando Clinical Research Center (OCRC)
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Age 18-65 years inclusive at the time of consent.
- Willingness to comply with any applicable contraceptive requirements of the protocol and is:
- Male, or
- Non pregnant, non lactating female
- Females must be at least 90 days post partum or nulliparous.
Subjects who do not have hepatic impairment (healthy subjects)
- Normal renal function.
Subjects with hepatic impairment
- Subjects must provide a letter of evaluation from a hepatologist or copy of supporting documents confirming the subject's hepatic impairment (a liver biopsy is preferable but not mandatory).
- Hepatic impairment should be primary and must not be a complication of an underlying primary systemic disease (eg, patients with metastatic cancer and cancer cachexia)
- Documented chronic stable liver impairment
Exclusion Criteria
Subjects who do not have hepatic impairment (healthy subjects)
- A positive HIV antibody screen, Hepatitis B surface antigen, or Hepatitis C virus antibody screen.
Subjects with hepatic impairment
- Presence of a hepatocellular carcinoma, or an acute hepatic disease caused by an infection or drug toxicity.
- Presence of surgically created or transjugular intrahepatic portal systemic shunts.
- A positive HIV antibody screen.
- Renal insufficiency.
All subjects
- Subject has a history of thyroid disorder.
- History of nephrotic syndrome.
- History of alcohol or other substance abuse within the last year.
- A positive screen for alcohol or drugs of abuse.
- Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day. (1 alcohol unit = 1 beer [12 oz/355 mL] = 1 wine [5 oz/150 mL] = 1 liquor [1.5 oz/40 mL] = 0.75 oz/20 mL alcohol.)
- Caffeine consumption: For healthy subjects: Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches or have a history of caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz/180 mL cup of coffee, two 12 oz/355 mL (ie, 24 oz/710 mL cola) cans of cola, one 12 oz/355 mL cup of tea, three 1 oz/28 g chocolate bars (ie, 3 oz/85 g chocolate). Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
- Donation of blood or blood products within 60 days.
- Substantial changes in eating habits within 30 days.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: SSP-004184 (Child-Pugh A Liver Impaired)
The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation.
Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy.
Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15.
It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
|
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Andre navne:
|
|
Eksperimentel: SSP-004184 (Child-Pugh B Liver Impaired)
|
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Andre navne:
|
|
Eksperimentel: SSP-004184 (Child-Pugh C Liver Impaired)
|
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Andre navne:
|
|
Eksperimentel: SSP-004184 (Matched Healthy Subjects)
|
All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Areal under plasmakoncentration-tidskurven (AUC) af SSP-004184
Tidsramme: Over 96 timer efter dosis
|
AUC kan bruges som et mål for lægemiddeleksponering.
Det er afledt af lægemiddelkoncentration og tid, så det giver et mål for, hvor meget og hvor længe et lægemiddel forbliver i en krop.
|
Over 96 timer efter dosis
|
|
Maksimal plasmakoncentration (Cmax) af SSP-004184
Tidsramme: Over 96 timer efter dosis
|
Cmax er et udtryk, der refererer til den maksimale (eller maksimale) koncentration, som et lægemiddel opnår i kroppen, efter at lægemidlet er blevet administreret.
|
Over 96 timer efter dosis
|
|
Time of Maximum Plasma Concentration (Tmax) for SSP-004184
Tidsramme: Over 96 hours post-dose
|
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.
|
Over 96 hours post-dose
|
|
Plasma Half-Life (T 1/2) of SSP-004184
Tidsramme: Over 96 hours post-dose
|
The time it takes for the blood plasma concentration of a substance to halve.
|
Over 96 hours post-dose
|
|
Total Body Clearance (CL/F) of SSP-004184
Tidsramme: Over 96 hours post-dose
|
The rate at which a drug is removed from the body.
|
Over 96 hours post-dose
|
|
Volume of Distribution (Vz/F) of SSP-004184
Tidsramme: Over 96 hours post-dose
|
The distribution of a medication between plasma and the rest of the body.
|
Over 96 hours post-dose
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
9. november 2012
Primær færdiggørelse (Faktiske)
1. april 2013
Studieafslutning (Faktiske)
1. april 2013
Datoer for studieregistrering
Først indsendt
19. november 2012
Først indsendt, der opfyldte QC-kriterier
21. november 2012
Først opslået (Skøn)
22. november 2012
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. juli 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
22. juni 2021
Sidst verificeret
1. juni 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- SPD602-105
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .